abrdn Life Sciences Investors is classed by the SEC under no industry code yet (industry code 0000). Its filings are on EDGAR under CIK 884121; the figures the desk reads are not on file yet.
Product businessfilings since 19951 of 9 filed, 8 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 0000, unclassified); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.6 out of ten, 1 of 9 metrics filed and 8 estimated: past 4.3 out of ten, present 4.5 out of ten, future 5.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 2.5 out of ten. 1 warning event since 2017; the latest 2023-09-12. 25th percentile among 4 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 15 of 100 (universe median). 50th percentile among 4559 sector filers. A CrossAssetData estimate, not a filed reading: universe median, confidence 15 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Shareholder treatment (past): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 15 of 100 (universe median). 50th percentile among 4091 sector filers. A CrossAssetData estimate, not a filed reading: universe median, confidence 15 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Financial health (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 15 of 100 (universe median). 50th percentile among 5052 sector filers. A CrossAssetData estimate, not a filed reading: universe median, confidence 15 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Industry position (present): 5.2 out of ten. CrossAssetData estimate 5.2/10, confidence 15 of 100 (universe median). 50th percentile among 4637 sector filers. A CrossAssetData estimate, not a filed reading: universe median, confidence 15 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Leadership (present): 2.5 out of ten. CrossAssetData estimate 2.5/10, confidence 35 of 100 (one part). 25th percentile among 4 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Room to expand (future): 4.9 out of ten. CrossAssetData estimate 4.9/10, confidence 15 of 100 (universe median). 50th percentile among 4453 sector filers. A CrossAssetData estimate, not a filed reading: universe median, confidence 15 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Growth drivers (future): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 15 of 100 (universe median). 50th percentile among 4519 sector filers. A CrossAssetData estimate, not a filed reading: universe median, confidence 15 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Expectations vs reality (future): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 15 of 100 (universe median). 50th percentile among 4118 sector filers. A CrossAssetData estimate, not a filed reading: universe median, confidence 15 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest filing: Form 40-17G, 2026-09-24. Filings on record since 1995. Read from EDGAR 2026-10-12.
Who runs it
Reilly, Heather Carter (Vice President); Pittard, Christian (President); Mahai, Chris Lavictoire (director). 3 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.